IL-22 has been shown to support the growth of mantle cell lymphoma [41], anaplastic large cell lymphoma [42], hepatocellular carcinoma [43] and colon carcinoma through STAT3 activation [44], [45]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.